Clinical trials: Irritation
IBS (Irritable Bowel Syndrome), Bloating
A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating
This study is a randomized, double-blind, placebo-controlled, within-individual crossover trial designed to assess the impact of regular use of a consumer-grade FODMAP-targeting digestive enzyme blend (FODZYME®) on…
- Conditions
- IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
- Trial name
- NCT07591584
- Testing
- FODMAP-targeting digestive enzyme blend
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kiwi Health Inc
Irritable Bowel Syndrome
Pain Relief In Irritable Bowel Syndrome
The purpose of this study is to determine whether Proklama is effective in significative reduction of pain, other symptoms IBS's related, and improves quality of life concerning IBS disease.
- Trial name
- PRITON (NCT02573844)
- Testing
- Proklama
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Geophyt S.r.l.s.
Hygiene
Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)
The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Femina Delicata.
- Trial name
- NCT00497692
- Testing
- Lactoserum
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Inflammatory Bowel Disease
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.
- Trial name
- NCT03555617
- Testing
- TD-1473, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Sensitivity, Contact, Photosensitivity
Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Photosensitization of a Scar Gel
Evaluate the potential of Primary Dermal Irritability, Accumulated Dermal Irritability, Dermal Sensitization, Photoallergy and Photosensitization, of health products through the application of Patch Test, proving the safety of…
- Conditions
- Sensitivity, Contact, Photosensitivity, Phototoxicity
- Trial name
- NCT06723340
- Testing
- Scar gel
- Where
- Brazil
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Herbarium Laboratorio Botanico Ltda
Dermal Irritation
14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
to determine the ability of the test article to cause irritation to the skin of humans under controlled patch test conditions
- Trial name
- NCT02737618
- Testing
- Trojan "Chameleon" Personal Lubricant
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Skin Irritation
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion Daily Advance to induce sensitization to the skin
- Trial name
- NCT01892423
- Testing
- Cetaphil Moisturizing Lotion Daily Advance
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Ocular Infections, Irritations and Inflammations
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- Hawaii-1 (NCT02163824)
- Testing
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%
- Where
- 23 sites in United States
- Volunteers
- 380 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Major Depressive Disorder and Irritability
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
- Trial name
- NCT02212613
- Testing
- Brexpiprazole
- Where
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism
Lurasidone Pediatric Autism Study
This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent…
- Trial name
- NCT01911442
- Testing
- Lurasidone 20 mg daily, Lurasidone
- Where
- 41 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Irritable Bowel Syndrome
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
The purpose of this study is to analyse the effect of a probiotic supplement on functional intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
- Trial name
- NCT01728610
- Testing
- Probiotic (Active high), Probiotic (Active low)
- Where
- 2 sites in Finland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- Danisco
Psoriasis Vulgaris
Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100
The purpose of this study is to determine the skin irritation potential and sensitisation potential of LEO 90100 and the vehicle after repeated applications on the skin of healthy subjects.
- Trial name
- NCT01935869
- Testing
- LEO 90100, Vehicle, Petrolatum ointment
- Where
- France
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Irritable Bowel Syndrome With Diarrhea
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-4 (NCT02120027)
- Testing
- Ibodutant 10 mg
- Where
- 139 sites in United States, Czechia and 7 more
- Volunteers
- 558 people
- Sponsor
- Menarini Group
Sensitivity, Contact
Dermatological Assessment of Primary Dermal Irritability Accumulated and Sensitization of Hyaluronic Nasal Spray
Evaluate the potential of Primary Dermal Irritability, Accumulated Dermal Irritability and Dermal Sensitization, of health products through the application of Patch Test, proving the safety of the product for topical use.
- Trial name
- NCT05508243
- Testing
- Hyaluronic Nasal Spray
- Where
- Brazil
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Herbarium Laboratorio Botanico Ltda
Peristomal Skin Complication
Preliminary Evaluation of CASTLE Barrier Prototype UK
The purpose of this study is to provide preliminary assessment of the safety and performance of a novel barrier formulation (CASTLE) in a small population of subjects with irritated peristomal skin.
- Trial name
- NCT01530087
- Testing
- CASTLE barrier
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Hollister Incorporated
Injection Site, Injection Site Reaction
Sorrel 25R Injector - Sorrel Clinical Study Protocol
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
- Conditions
- Injection Site, Injection Site Reaction, Injection Site Irritation
- Trial name
- NCT05221333
- Testing
- Sorrel Wearable Injector
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eitan Medical
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
Skin Irritation
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+.
- Trial name
- NCT01892657
- Testing
- Facial Moisturizer with SPF 50+
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Irritable Bowel Syndrome (IBS)
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
- Trial name
- NCT00394186
- Testing
- GW427353
- Where
- 19 sites in Australia, France and 1 more
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline